Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial

Journal of the American Heart Association
Gilles R DagenaisSalim Yusuf

Abstract

It is not clear whether the effects of lipid-lowering or antihypertensive medications are influenced by adherence to healthy lifestyle factors. We assessed the effects of both drug interventions in subgroups by the number of healthy lifestyle factors in participants in the HOPE-3 (Heart Outcomes Prevention Evaluation) trial. In this primary prevention trial, 4 healthy lifestyle factors (nonsmoking status, physical activity, optimal body weight, and healthy diet) were recorded in 12 521 participants who were at intermediate risk of cardiovascular disease (CVD) and were randomized to rosuvastatin, candesartan/hydrochlorothiazide, their combination, or matched placebos. Median follow-up was 5.6 years. The outcome was a composite of CVD events. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox regression models. Participants with ≥2 healthy lifestyle factors had a lower rate of CVD compared with those with fewer factors (HR: 0.85; 95% CI, 0.73-1.00). Rosuvastatin reduced CVD events in participants with ≥2 healthy lifestyle factors (HR: 0.74; 95% CI, 0.62-0.90) and in participants with <2 factors (HR: 0.79; 95% CI, 0.61-1.01). Consistent results were observed with combination therapy (≥2 factor...Continue Reading

References

Jul 7, 2000·The New England Journal of Medicine·M J StampferW C Willett
Jun 27, 2003·The New England Journal of Medicine·Antonia TrichopoulouDimitrios Trichopoulos
Sep 24, 2004·JAMA : the Journal of the American Medical Association·Kim T B KnoopsWija A van Staveren
Sep 18, 2008·BMJ : British Medical Journal·Rob M van DamFrank B Hu
Oct 15, 2009·Asia-Pacific Journal of Public Health·Ok Kyung Ham, Sook Ja Yang
Apr 5, 2016·The New England Journal of Medicine·Salim YusufUNKNOWN HOPE-3 Investigators
Apr 5, 2016·The New England Journal of Medicine·Salim YusufUNKNOWN HOPE-3 Investigators
Apr 5, 2016·The New England Journal of Medicine·Eva M LonnUNKNOWN HOPE-3 Investigators
Dec 14, 2016·The New England Journal of Medicine·Amit V KheraSekar Kathiresan

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00239681

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Related Papers

International Journal of Epidemiology
Sanne Ae PetersChina Kadoorie Biobank collaboration group (members listed at end of report)
European Journal of Heart Failure
Orly VardenyProspective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF
© 2022 Meta ULC. All rights reserved